TargetBeta
ADAM9
ADAM metallopeptidase domain 9 · also MDC9, KIAA0021, MCMP, Mltng · ADAM metallopeptidase domain containing
3 programs in company-led studies act on ADAM9, from 3 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Anti-ADAM9/Exatecan Antibody-drug Conjugate MGC028rule | MacroGenics | – | phase 1 | 11 running | – | NCIt |
| Anti-ADAM9/Pamirtecan Antibody-drug Conjugate DB-1317rule | DualityBio | – | phase 1 | 11 running | – | NCIt |
| Anti-ADAM9/Topoisomerase-1 Inhibitor Antibody-drug Conjugate BG-C0979rule | BeOne Medicines | – | phase 1 | 11 running | – | NCIt |
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026Anti-ADAM9/Exatecan Antibody-drug Conjugate MGC028 · MacroGenics · phase 1 · NCT06723236
- Jun 2028Anti-ADAM9/Pamirtecan Antibody-drug Conjugate DB-1317 · DualityBio · phase 1 · NCT07141706
- Apr 30, 2029Anti-ADAM9/Topoisomerase-1 Inhibitor Antibody-drug Conjugate BG-C0979 · BeOne Medicines · phase 1 · NCT07414836
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.